Verso Paper Inc. Form 424B3 July 11, 2014 Table of Contents

> Filed Pursuant to Rule 424(b)(3) Registration No. 333-193794

JOINT PROXY AND INFORMATION STATEMENT/PROSPECTUS PROPOSED MERGER YOUR VOTE IS IMPORTANT

Dear Stockholders of Verso Paper Corp.:

On December 28, 2013, the board of directors of Verso Paper Corp., or Verso, approved an Agreement and Plan of Merger, which was subsequently entered into on January 3, 2014, referred to as the Merger Agreement, providing for Verso to acquire NewPage Holdings Inc., or NewPage, which transaction is referred to as the Merger. The Merger Agreement was separately approved by the NewPage board of directors at a meeting on January 1, 2014 and subsequently by unanimous written consent on January 3, 2014.

Pursuant to the Merger Agreement, (a) approximately \$243 million in cash was paid to holders of NewPage common stock as a dividend prior to the date of this joint proxy and information statement/prospectus, which is referred to as the Recapitalization Dividend, with the remaining approximately \$7 million of the \$250 million total cash consideration contemplated by the Merger Agreement paid into an escrow account for the benefit of holders of NewPage restricted stock units upon vesting and holders of NewPage stock options upon consummation of the Merger, and (b) each share of common stock of NewPage outstanding immediately prior to the effective time of the Merger (other than treasury shares of NewPage and any shares of NewPage common stock owned by Verso or any subsidiary of Verso or NewPage, and other than shares of common stock as to which dissenters—rights have been properly exercised pursuant to the General Corporation Law of the State of Delaware) will be converted into the right to receive its pro rata portion of:

the remainder, if any, of the approximately \$7 million in cash paid into the escrow account, plus the cash actually received by NewPage in respect of any exercises of NewPage stock options between the date of the Merger Agreement and the closing of the Merger;

\$650 million in principal amount of New First Lien Notes (subject to downward adjustment in certain circumstances in an amount not to exceed \$27 million in value); and

shares of Verso common stock representing 20% (subject to upward adjustment in certain circumstances to no greater than 25%) of the sum of (x) the number of outstanding Verso shares as of immediately prior to closing of the Merger plus (y) the number of shares, if any, underlying vested, in-the-money Verso stock

options as of the signing of the Merger Agreement.

The New First Lien Notes, Verso common stock, cash received from option exercises prior to closing and the remainder of cash in the escrow account at closing are referred to as the Merger Consideration, and the Merger Consideration together with the Recapitalization Dividend and any portion of cash from the escrow account paid in respect of restricted stock units upon vesting prior to closing are referred to as the Transaction Consideration. The cash portions of the Transaction Consideration (other than cash received from option exercises prior to closing) were funded from the proceeds of a new \$750 million bank borrowing that was also used to refinance NewPage s former \$500 million term loan facility. See The Merger Agreement Transaction Consideration for more details.

As of the date of this joint proxy and information statement/prospectus, the number of shares of Verso common stock to be issued to NewPage stockholders would be approximately 14.0 million in the aggregate, assuming a 100% participation of aggregate principal amount of Old Second Lien Notes in the Second Lien Notes Exchange Offer and a 100% participation of aggregate principal amount of Old Subordinated Notes in the Subordinated Notes Exchange Offer, and that the number of shares of Verso common stock issued as part of the Merger Consideration is not further adjusted upwards. See Description of Other Indebtedness Exchange Offer Transactions for more details. The Verso common stock is listed for trading on the New York Stock Exchange under the symbol VRS. The implied value of the stock portion of the Merger Consideration will fluctuate as the market price of Verso common stock fluctuates. The number of shares of Verso common stock issuable to each NewPage stockholder will be rounded up or down to the nearest whole number of shares, and no fractional shares or cash in lieu of fractional shares will be paid by Verso.

The value of the portion of the Merger Consideration represented by the New First Lien Notes may be adversely affected by several factors identified in this joint proxy and information statement/prospectus, and we

cannot assure you that an active market for the notes will develop or continue. Additionally, the amount of New First Lien Notes to be issued in the Merger is subject to downward adjustment, in an amount not to exceed \$27 million in value, if NewPage makes certain restricted payments between September 30, 2013 and the closing of the Merger. No denomination of New First Lien Notes less than \$2,000 will be issued in the Merger, but in lieu thereof each holder of NewPage common stock otherwise entitled to a lower amount of New First Lien Notes will have the aggregate amount of such New First Lien Notes to be issued to such holder equitably adjusted (by rounding up or down to the nearest whole denomination or increment, as appropriate) such that the holders of NewPage common stock only receive New First Lien Notes in denominations of \$2,000 with fully integral multiples of \$1,000 in excess of \$2,000, with no adjustment to the aggregate amount of New First Lien Notes issuable in the Merger.

Verso is soliciting proxies for use at a special meeting of its stockholders where they will be asked to consider and vote on proposals to (1) approve the issuance of shares of Verso common stock to the NewPage stockholders as part of the Merger Consideration pursuant to the Merger Agreement; (2) approve the issuance of Verso Warrants to the holders of Old Second Lien Notes participating in the Second Lien Notes Exchange Offer, and shares of Verso common stock issuable upon the conversion of such Verso Warrants immediately prior to the consummation of the Merger and the issuance of shares of Verso common stock as part of the Merger Consideration, as each such term is defined in this joint proxy and information statement/prospectus; (3) approve the issuance of Verso Warrants to the holders of Old Subordinated Notes participating in the Subordinated Notes Exchange Offer, and shares of Verso common stock issuable upon the conversion of such Verso Warrants immediately prior to the consummation of the Merger and the issuance of shares of Verso common stock as part of the Merger Consideration, as each such term is defined in this joint proxy and information statement/prospectus; (4) approve Verso s Amended and Restated 2008 Incentive Award Plan; (5) approve and adopt the amendment of Verso s Amended and Restated Certificate of Incorporation to change its corporate name to Verso Corporation effective upon the consummation of the Merger; and (6) approve any adjournment of the Verso special meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve Proposal 1 at the time of the Verso special meeting.

Certain of NewPage s stockholders who owned approximately 61% of the voting power of NewPage common stock on January 3, 2014 have entered into support agreements with NewPage and Verso pursuant to which such stockholders have agreed to vote their shares of NewPage common stock or execute a written consent in favor of the adoption and approval of the Merger Agreement. NewPage expects to receive the requisite written consents from those stockholders promptly after receiving the request of NewPage and/or Verso following the effectiveness of the registration statement of which this joint proxy and information statement/prospectus is a part.

After careful consideration, on December 28, 2013, the Verso board of directors unanimously approved the Merger Agreement, the Merger and the transactions contemplated by the Merger Agreement, and declared that the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of Verso and its stockholders. **The Verso board of directors unanimously recommends that you vote FOR each of Proposals 1-6 as described above and elsewhere in this joint proxy and information statement/prospectus.**

Your vote is important, regardless of the number of shares that you own. The Merger cannot be completed without the approval of the Verso stockholders. Verso is holding a special meeting of its stockholders to vote on, among other things, a proposal necessary to complete the Merger. More information about Verso, NewPage, the Merger Agreement, the Merger and the special meeting of Verso stockholders is contained in this joint proxy and information statement/prospectus. We encourage you to read this document carefully before voting, including the section entitled Risk Factors beginning on page 47. Regardless of whether you plan to attend the Verso special meeting, please take the time to vote your securities in accordance with the instructions contained in this document.

For a discussion of risk factors you should consider in evaluating the Merger Agreement and the proposals you are being asked to adopt, see <u>Risk Factors</u> beginning on page 47 of this joint proxy and information statement/prospectus.

Sincerely,

David J. Paterson President and Chief Executive Officer

Verso Paper Corp.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Merger described in this joint proxy and information statement/prospectus nor have they approved or disapproved of the issuance of the Verso common stock in connection with the Merger, or determined if this joint proxy and information statement/prospectus is accurate or complete. Any representation to the contrary is a criminal offense.

This joint proxy and information statement/prospectus is dated July 11, 2014 and is first being mailed on or about July 11, 2014.

INFORMATION STATEMENT

NOTICE OF EXPECTED ACTION BY WRITTEN CONSENT AND APPRAISAL RIGHTS PROPOSED MERGER WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

Dear Stockholders of NewPage Holdings Inc.:

The board of directors of NewPage Holdings Inc., or NewPage, at a meeting on January 1, 2014 (with one director absent) and subsequently by unanimous written consent on January 3, 2014, approved the Agreement and Plan of Merger, which was subsequently entered into on January 3, 2014, referred to as the Merger Agreement, providing for NewPage to be acquired by Verso Paper Corp., or Verso, which transaction is referred to as the Merger. The Merger Agreement was separately approved by Verso s board of directors on December 28, 2013.

Pursuant to the Merger Agreement, (a) approximately \$243 million in cash was paid to holders of NewPage common stock as a dividend prior to the date of this joint proxy and information statement/prospectus, which is referred to as the Recapitalization Dividend, with the remaining approximately \$7 million of the \$250 million total cash consideration contemplated by the Merger Agreement paid into an escrow account for the benefit of holders of NewPage restricted stock units upon vesting and holders of NewPage stock options upon consummation of the Merger, and (b) each share of common stock of NewPage outstanding immediately prior to the effective time of the Merger (other than treasury shares of NewPage and any shares of NewPage common stock owned by Verso or any subsidiary of Verso or NewPage, and other than shares of common stock as to which dissenters—rights have been properly exercised pursuant to the General Corporation Law of the State of Delaware) will be converted into the right to receive its pro rata portion of:

the remainder, if any, of the approximately \$7 million in cash paid into the escrow account, plus the cash actually received by NewPage in respect of any exercises of NewPage stock options between the date of the Merger Agreement and the closing of the Merger;

\$650 million in principal amount of New First Lien Notes (subject to downward adjustment in certain circumstances in an amount not to exceed \$27 million in value); and

shares of Verso common stock representing 20% (subject to upward adjustment in certain circumstances to no greater than 25%) of the sum of (x) the number of outstanding Verso shares as of immediately prior to closing of the Merger plus (y) the number of shares, if any, underlying vested, in-the-money Verso stock options as of the signing of the Merger Agreement.

The New First Lien Notes, Verso common stock, cash received from option exercises prior to closing and the remainder of cash in the escrow account at closing are referred to as the Merger Consideration, and the Merger Consideration together with the Recapitalization Dividend and any portion of cash from the escrow account paid in

respect of restricted stock units upon vesting prior to closing are referred to as the Transaction Consideration. The cash portions of the Transaction Consideration (other than cash received from option exercises prior to closing) were funded from the proceeds of a new \$750 million bank borrowing that was also used to refinance NewPage s former \$500 million term loan facility. See The Merger Agreement Transaction Consideration for more details.

As of the date of this joint proxy and information statement/prospectus, the number of shares of Verso common stock to be issued to NewPage stockholders would be approximately 14.0 million in the aggregate, assuming a 100% participation of aggregate principal amount of Old Second Lien Notes in the Second Lien Notes Exchange Offer and a 100% participation of aggregate principal amount of Old Subordinated Notes in the Subordinated Notes Exchange Offer, and that the number of shares of Verso common stock issued as part of the Merger Consideration is not further adjusted upwards. See Description of Other Indebtedness Exchange Offer Transactions for more details. The Verso common stock is listed for trading on the New York Stock Exchange under the symbol VRS. The implied value of the stock portion of the Merger Consideration will fluctuate as the market price of Verso common stock fluctuates. The number of shares of Verso common stock issuable to each NewPage shareholder will be rounded up or down to the nearest whole number of shares, and no fractional shares or cash in lieu of fractional shares will be issued or paid by Verso.

The value of the portion of the Merger Consideration represented by the New First Lien Notes may be adversely affected by several factors identified in the Information Statement, and we cannot assure you that an active market for the notes will develop or continue. Additionally, the amount of New First Lien Notes to be issued in the Merger is subject to downward adjustment, in an amount not to exceed \$27 million in value, if NewPage makes certain restricted payments between September 30, 2013 and the closing of the Merger. No denomination of New First Lien Notes (as defined in the information statement enclosed with this letter, the Information Statement) less than \$2,000 will be issued in the Merger, but in lieu thereof each holder of NewPage common stock otherwise entitled to a lower amount of New First Lien Notes will have the aggregate amount of such New First Lien Notes to be issued to such holder equitably adjusted (by rounding up or down to the nearest whole denomination or increment, as appropriate) such that the holders of NewPage common stock only receive New First Lien Notes in denominations of \$2,000 with fully integral multiples of \$1,000 in excess of \$2,000, with no adjustment to the aggregate amount of New First Lien Notes issuable in the Merger.

As of the date of this joint proxy and information statement/prospectus, NewPage has 7,092,477 shares of common stock issued and outstanding. Each of such shares is entitled to one vote on the Merger. The adoption and approval of the Merger Agreement requires the affirmative vote or written consent of the holders of a majority of NewPage s issued and outstanding common stock. On January 3, 2014, certain of NewPage s stockholders which collectively owned 4,299,808 shares, which represented approximately 61% of the voting power of NewPage common stock, entered into support agreements with NewPage and Verso pursuant to which such stockholders have agreed to vote their shares of NewPage common stock or execute a written consent in favor of the adoption and approval of the Merger Agreement. NewPage expects to receive the requisite written consents from those stockholders promptly after receiving the request of NewPage and/or Verso following the effectiveness of the registration statement of which the Information Statement is a part. If NewPage receives written consents from such stockholders, no further action by any other NewPage stockholders would be required to adopt the Merger Agreement or to authorize the transactions contemplated thereby. For this reason, the Information Statement is being provided to you for informational purposes only. NewPage has not solicited and is not soliciting your adoption and approval of the Merger Agreement.

Under Delaware law, if you comply with certain requirements of Delaware law described in the accompanying Information Statement, you will have the right to seek an appraisal and to be paid the fair value of your shares of NewPage common stock as determined in accordance with Delaware law (exclusive of any element of value arising from the accomplishment or expectation of the Merger) instead of the Merger Consideration. Your appraisal rights under Delaware law are more fully described in the accompanying Information Statement under The Merger NewPage Stockholder Appraisal Rights beginning on page 253.

The Information Statement includes important information about NewPage, Verso and the Merger, including the existence of several conditions to NewPage s obligations and those of Verso s to complete the Merger, all of which must be either satisfied or waived prior to the completion of the Merger, and should be read carefully and in its entirety. Neither the Information Statement, nor any other information you receive from NewPage in respect of the Merger, is intended to be legal, tax or investment advice. Accordingly, you should consult your own legal counsel, accountants and investment advisors as to legal, tax and other matters concerning the Merger.

This notice and the accompanying Information Statement shall constitute notice to you of the action by written consent contemplated by Section 228 of the Delaware General Corporation Law.

Sincerely,

Mark A. Angelson Chairman of the Board

NewPage Holdings Inc.

Neither the Securities and Exchange Commission nor any state securities regulatory agency has approved or disapproved the Merger, passed upon the merits or fairness of the Merger Agreement or the transactions contemplated thereby, including the proposed Merger, or passed upon the adequacy or accuracy of the information contained in this document or the accompanying Information Statement. Any representation to the contrary is a criminal offense.

The accompanying Information Statement is dated July 11, 2014 and is first being mailed to NewPage s stockholders on or about July 11, 2014.

VERSO PAPER CORP.

6775 Lenox Center Court, Suite 400

Memphis, TN 38115-4436

NOTICE OF

SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON JULY 30, 2014

NOTICE IS HEREBY GIVEN that a special meeting of the stockholders of Verso Paper Corp., or Verso, will be held at 10:00 a.m., Central Time, on July 30, 2014, at Verso s office located at 6775 Lenox Center Court, Memphis, Tennessee. Holders of record of Verso common stock at the close of business on July 2, 2014 (such date and time, the record date) will be asked to consider and vote on the following proposals:

- Proposal 1. approve the issuance of shares of Verso common stock to the stockholders of NewPage Holdings Inc., or NewPage, as part of the Merger Consideration pursuant to the Agreement and Plan of Merger dated as of January 3, 2014, among NewPage, Verso and Verso Merger Sub Inc., or Merger Sub, pursuant to which Merger Sub will merge with and into NewPage and NewPage will continue as the surviving corporation and an indirect, wholly owned subsidiary of Verso, which transaction is referred to as the Merger;
- Proposal 2. approve the issuance of Verso Warrants to the holders of Old Second Lien Notes participating in the Second Lien Notes Exchange Offer, and shares of Verso common stock issuable upon the conversion of such Verso Warrants immediately prior to the consummation of the Merger and the issuance of shares of Verso common stock as part of the Merger Consideration, as each such term is defined in this joint proxy and information statement/prospectus;
- Proposal 3. approve the issuance of Verso Warrants to the holders of Old Subordinated Notes participating in the Subordinated Notes Exchange Offer, and shares of Verso common stock issuable upon the conversion of such Verso Warrants immediately prior to the consummation of the Merger and the issuance of shares of Verso common stock as part of the Merger Consideration, as each such term is defined in this joint proxy and information statement/prospectus;
- Proposal 4. approve Verso s Amended and Restated 2008 Incentive Award Plan;
- Proposal 5. approve and adopt the amendment of Verso s Amended and Restated Certificate of Incorporation to change its corporate name to Verso Corporation effective upon the consummation of the Merger; and
- Proposal 6. approve any adjournment of the Verso special meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve Proposal 1 at the time of the Verso special meeting.

Please refer to the attached joint proxy and information statement/prospectus and the attached materials for further information with respect to the business to be transacted at the Verso special meeting. Verso expects to transact no other business at the meeting. Holders of record of Verso common stock as of the record date will be entitled to receive notice of and to vote at the Verso special meeting.

The Verso board of directors unanimously recommends that you vote FOR each of Proposals 1-6 as described in the accompanying joint proxy and information statement/prospectus.

Your vote is important, regardless of the number of shares that you own. Whether or not you plan on attending the Verso special meeting, we urge you to read the joint proxy and information statement/prospectus carefully and to please vote your shares as promptly as possible. You may vote your shares by proxy electronically via the Internet, by telephone, by completing and sending in the appropriate paper proxy card or in person at the Verso special meeting.

All Verso stockholders as of the record date are cordially invited to attend the Verso special meeting.

By Order of the Board of Directors,

Peter H. Kesser Secretary

July 11, 2014

REFERENCES TO ADDITIONAL INFORMATION

This joint proxy and information statement/prospectus incorporates by reference important business and financial information about Verso from documents that Verso has filed or will file with the Securities and Exchange Commission, or the SEC, but that are not being included in or delivered with this joint proxy and information statement/prospectus. This information is available to you without charge upon your written or oral request. You may read and copy documents and other information about Verso that is filed with the SEC under the Securities and Exchange Act of 1934, or the Exchange Act, at the SEC s Public Reference Room at 100 F Street, N.E., Washington, DC 20549. You can also obtain such documents free of charge through the SEC s website, www.sec.gov, or by requesting them in writing or by telephone at the following address and telephone number:

By Mail: Verso Paper Corp.

6775 Lenox Center Court

Suite 400

Memphis, Tennessee 38115-4436 Attention: Investor Relations

By Telephone: (901) 369-4100

In order to obtain timely delivery, you must request such documents and other information no later than five business days before July 30, 2014.

For additional information, please see Where You Can Find More Information beginning on page 415. Please note that information contained on the website of Verso is not incorporated by reference in, nor considered to be part of, this joint proxy and information statement/prospectus.

ABOUT THIS JOINT PROXY AND INFORMATION STATEMENT/PROSPECTUS

Verso has supplied all information contained in this joint proxy and information statement/prospectus relating to Verso and the combined company, including combined company synergies or synergy assumptions or restructuring costs. NewPage has supplied all information contained in this joint proxy and information statement/prospectus relating to NewPage. Verso and NewPage have both contributed to information relating to the Merger.

You should rely only on the information contained in this joint proxy and information statement/prospectus provided by Verso and on the information contained in this joint proxy and information statement/prospectus provided by NewPage. No one has been authorized to provide you with information that is different from that contained in this joint proxy and information statement/prospectus provided by Verso and information contained in this joint proxy and information statement/prospectus is dated July 11, 2014, and is based on information as of such date or such other date as may be noted. You should not assume that the information contained in this joint proxy and information statement/prospectus provided by Verso or contained in this joint proxy and information statement/prospectus provided by NewPage is accurate as of any other date. Neither the mailing of this joint proxy and information statement/prospectus to the stockholders of NewPage nor the taking of any actions contemplated hereby by Verso or NewPage at any time will create any implication to the contrary.

This joint proxy and information statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction in which or from any person to whom it is unlawful to make any

such offer or solicitation in such jurisdiction.

TABLE OF CONTENTS

DEFINED TERMS	Page 1
QUESTIONS AND ANSWERS FOR VERSO STOCKHOLDERS	5
QUESTIONS AND ANSWERS TO NEWPAGE STOCKHOLDERS ABOUT THE MERGER	10
SUMMARY	13
The Companies	13
Vote Required	16
Merger and Merger Agreement	16
Transaction Consideration	16
Ancillary Agreements	17
Verso Board of Directors Reasons for the Merger	17
NewPage Board of Directors Reasons for the Merger	17
Fairness Opinion of Financial Advisor to NewPage	18
Fairness Opinion of Financial Advisor to Verso	18
Solvency Opinion of Financial Advisor to Verso	18
Treatment of NewPage Stock Options and Other Stock-Based Awards	18
Interests of NewPage Directors and Executive Officers in the Merger	19
Interests of Verso Directors and Executive Officers in the Merger	20
Conditions to the Completion of the Merger	20
Regulatory Approvals Required to Complete the Merger	21
Financing	22
Use of Proceeds of NewPage Term Loan Facility	22
Exchange Offer Transactions	23
Shared Services Agreement	25
Termination of the Merger Agreement	26
Non-Solicitation of Alternative Proposals	27
Expenses and Termination Fees Relating to the Merger	28
Accounting Treatment of the Merger	29
Certain Material U.S. Federal Income Tax Consequences of the Merger	29
Comparison of the Rights of Holders of Verso Common Stock and NewPage Common Stock	29
Appraisal Rights in Connection with the Merger	29
SUMMARY HISTORICAL AND PRO FORMA FINANCIAL DATA	30
Summary Historical Consolidated Financial Data of Verso	30
Summary Historical Consolidated Financial Data of Verso Holdings	33
Summary Historical Consolidated Financial Data of NewPage and Predecessor	36
Summary Unaudited Pro Forma Condensed Combined Financial Information of Verso	39
Summary Unaudited Pro Forma Condensed Combined Financial Information of Verso Holdings	42
COMPARATIVE PER SHARE DATA	45
MARKET PRICE AND DIVIDEND INFORMATION	46
RISK FACTORS	47

Risks Relating to the Merger	47
Risks Relating to Verso s Indebtedness	56
Risks Relating to the Combined Company Following the Merger	58
Risks Relating to the Verso Common Stock	65
Risks Relating to the New First Lien Notes	66
Risks Relating to Verso s Indebtedness Following the Merger	78
DESCRIPTION OF OTHER INDEBTEDNESS	79
Existing ABL Facility	79
Existing Cash Flow Facility	80

i

TABLE OF CONTENTS

(continued)

	Page
Amendments to Existing ABL Facility and Existing Cash Flow Facility in Contemplation	
of the Merger	82
11.75% Senior Secured Notes due 2019	82
11.75% Secured Notes due 2019	82
New Second Lien Notes	83
New Subordinated Notes	84
Old Second Lien Notes	85
Old Subordinated Notes	86
Second Priority Senior Secured Floating Rate Notes	86
Verso Quinnesec REP LLC	86
Non-Core Energy Financing	86
NewPage Term Loan Facility	87
NewPage ABL Facility	89
Financing Transactions in Connection with the Merger	90
Exchange Offer Transactions	90
REGARDING FORWARD-LOOKING STATEMENTS	94
SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF VERSO AND VERSO	
<u>HOLDINGS</u>	95
Selected Historical Consolidated Financial Data of Verso	95
Selected Historical Consolidated Financial Data of Verso Holdings	97
SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF NEWPAGE AND	
PREDECESSOR	99
Selected Financial Data	99
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION	101
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION	109
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF	
<u>OPERATIONS</u>	118
<u>BUSINESS</u>	137
VERSO STOCKHOLDERS	146
DIRECTORS AND EXECUTIVE OFFICERS	148
BOARD OF DIRECTORS AND CORPORATE GOVERNANCE	155
AUDIT COMMITTEE REPORT	162
AUDIT AND NON-AUDIT SERVICES AND FEES OF INDEPENDENT REGISTERED	
PUBLIC ACCOUNTING FIRM	163
COMPENSATION COMMITTEE REPORT	164
COMPENSATION DISCUSSION AND ANALYSIS	165
EXECUTIVE COMPENSATION	178
DIRECTOR COMPENSATION	191
COMPARATIVE PER SHARE DATA	193
MARKET PRICE AND DIVIDEND INFORMATION	194
VERSO SPECIAL MEETING	195

ii

TABLE OF CONTENTS

(continued)

DD ODOGA I G GUDA WEEDED TO MEDGO GEOGRANOI DEDG	Page
PROPOSALS SUBMITTED TO VERSO STOCKHOLDERS Proposals Assessed of Language of Stockholders Stockholders Stockholders	202
Proposal 1 Approval of Issuance of Shares of Verso Common Stock as Part of Merger Consideration	202
Pursuant to Merger Agreement Proposal 2 Agreement Stock Joseph Stock Joseph Jo	202
Proposal 2 Approval of Issuance of Verso Warrants and Shares of Verso Common Stock Issuable upon	202
Mandatory Conversion of such Verso Warrants pursuant to Second Lien Notes Exchange Offer Proposal 3 Approval of Issuance of Verso Warrants and Shares of Verso Common Stock Issuable upon	202
* **	202
Mandatory Conversion of such Verso Warrants pursuant to Subordinated Notes Exchange Offer Proposal 4 Approval of Verso s Amended and Restated 2008 Incentive Award Plan	202
Proposal 5 Approval and Adoption of Amendment of Verso s Amended and Restated Certificate	202
* **	212
of Incorporation to Change Corporate Name to Verso Corporation Effective Upon Consummation of Merger Proposal 6 Approval of Adjournment of Verso Special Meeting	
Proposal of Approval of Adjournment of Verso Special Meeting	212
THE MERGER	213
Effects of the Merger	213
<u>Financing for the Merger</u>	214
Exchange Offer Transactions	215
Background of the Merger	217
Recommendation of the NewPage Board of Directors and NewPage s Reasons for the Merger	222
Fairness Opinion of Financial Advisor to NewPage	226
Financial Forecasts	231
Recommendation of the Verso Board of Directors and Verso s Reasons for the Merger	232
Opinion of Evercore Group L.L.C.	234
Solvency Opinion	242
Interests of NewPage Directors and Executive Officers in the Merger	245
Payments to Verso Executive Officers Contingent Upon the Merger	249
Golden Parachute Compensation	249
Board of Directors and Officers of Verso after the Merger	251
Regulatory Approvals	251
New York Stock Exchange Listing of Verso Common Stock Issued in the Merger	252
Exchange of Shares of NewPage Common Stock	252
Fractional Shares	252
Minimum Denomination of New First Lien Notes	253
NewPage Stockholder Appraisal Rights	253
Accounting Treatment of the Merger	257
Certain Material U.S. Federal Income Tax Consequences	257
THE MERGER AGREEMENT	266
Effective Time; Closing Date	266
Effect of the Merger	266
<u>Transaction Consideration</u>	266
Treatment of Stock Options and Other Stock-Based Awards	268
Exchange and Payment Procedures	269

Representations and Warranties	270
Conduct of Business between Signing and Closing	272
Access to Verso and NewPage Businesses between Signing and Closing	275
Exclusivity; Alternative Transactions	275
Regulatory Approvals	276

iii

TABLE OF CONTENTS

(continued)

Financing Provisions 276 Indemnification; Directors and Officers and Fiduciary Liability Insurance 279 Employee Benefits 279 Shareholder Litigation 280 Stock Exchange Listing 280 Conditions to the Merger 280 Termination of NewPage and Verso Capitalization 280 Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law; Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 AGREEMENT 286 NewPage Stockholders Support Agreement 286 Verso Stockholders Support Agreement 286 Verso Stockholders s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Regulatory Filing Letter 289 Asset Financing Letter 289 Cooperation Agreement 290 BESCRIPTION O		Page
Employee Benefits 279 Shareholder Litigation 280 Stock Exchange Listing 280 Confirmation of NewPage and Verso Capitalization 280 Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholders Support Agreements 286 Verso Stockholders Support Agreements 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 377 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Prefe	<u>Financing Provisions</u>	276
Shareholder Litigation 280 Stock Exchange Listing 280 Confirmation of NewPage and Verso Capitalization 280 Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholder's Support Agreements 286 Verso Stockholder's Support Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 378 Transfer Agent and Registrar 379 Exchange Listing	· · · · · · · · · · · · · · · · · · ·	
Stock Exchange Listing 280 Confirmation of NewPage and Verso Capitalization 280 Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 AGREEMENT 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Registration Rights Agreement 378 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and R	• • • • • • • • • • • • • • • • • • •	
Confirmation of NewPage and Verso Capitalization 280 Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholders 286 Verso Stockholders 286 Verso Stockholders 287 Regulatory Filing Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 378 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK COMMON STOCK		
Conditions to the Merger 280 Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 GREEMENT 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 280 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 378 Eachange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE <t< td=""><td></td><td></td></t<>		
Termination 282 Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholders Support Agreements 286 NewPage Stockholder's Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 379 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 380 COMMON STOCK 380		
Termination Fees 283 Specific Performance 284 Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 378 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK INFORMATION ABOUT VERSO 390 <	<u> </u>	
Specific Performance 284 Governing Law; Jurisdiction; Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 AGREEMENT 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 280 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 379 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380		
Governing Law: Jurisdiction: Waiver of Jury Trial 284 Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 NewPage Stockholders Support Agreements 286 NewPage Stockholder's Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 379 Cretain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 </td <td></td> <td></td>		
Legal Status of Debt Financing Sources 285 ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER 286 AGREEMENT 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Referred Stock 377 Registration Rights Agreement 378 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 380 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT VERSO 391 Description of Busin		
ANCILLARY AGREEMENTS ENTERED INTO IN CONNECTION WITH THE MERGER AGREEMENT AGREEMENT AGREEMENT Begulatory Begulatory Filing Letter Begulatory Filing Letter Begulatory B		
AGREEMENT 286 NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSQ 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	Legal Status of Deot Financing Sources	203
NewPage Stockholders Support Agreements 286 Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 378 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK OMMON STOCK 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
Verso Stockholder s Voting Agreement 286 Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
Lock-Up Side Letter 287 Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK OMMON STOCK 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	*	
Regulatory Filing Letter 287 Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK COMMON STOCK 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
Director Appointment Letter 289 Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	*	
Asset Financing Letter 289 Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
Cooperation Agreement 289 Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK COMMON STOCK 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	**	
Release Agreement 290 DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
DESCRIPTION OF THE NEW FIRST LIEN NOTES 291 BOOK-ENTRY; DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391		
BOOK-ENTRY: DELIVERY AND FORM 375 DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	Release Agreement	290
DESCRIPTION OF VERSO CAPITAL STOCK 377 Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	DESCRIPTION OF THE NEW FIRST LIEN NOTES	291
Common Stock 377 Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	BOOK-ENTRY; DELIVERY AND FORM	375
Preferred Stock 377 Registration Rights Agreement 377 Certain Corporate Anti-Takeover Provisions 378 Transfer Agent and Registrar 379 Exchange Listing 379 COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE 380 INFORMATION ABOUT VERSO 390 INFORMATION ABOUT NEWPAGE 391 Description of Business 391	DESCRIPTION OF VERSO CAPITAL STOCK	377
Registration Rights Agreement377Certain Corporate Anti-Takeover Provisions378Transfer Agent and Registrar379Exchange Listing379COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK380INFORMATION ABOUT VERSO390INFORMATION ABOUT NEWPAGE391Description of Business391	Common Stock	377
Certain Corporate Anti-Takeover Provisions378Transfer Agent and Registrar379Exchange Listing379COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE380COMMON STOCK380INFORMATION ABOUT VERSO390INFORMATION ABOUT NEWPAGE391Description of Business391	Preferred Stock	377
Transfer Agent and Registrar379Exchange Listing379COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK380INFORMATION ABOUT VERSO390INFORMATION ABOUT NEWPAGE391Description of Business391	Registration Rights Agreement	377
Exchange Listing COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK INFORMATION ABOUT VERSO INFORMATION ABOUT NEWPAGE Description of Business 379 380 390 391	Certain Corporate Anti-Takeover Provisions	378
COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE COMMON STOCK INFORMATION ABOUT VERSO INFORMATION ABOUT NEWPAGE Description of Business 390 391	Transfer Agent and Registrar	379
COMMON STOCK380INFORMATION ABOUT VERSO390INFORMATION ABOUT NEWPAGE391Description of Business391	Exchange Listing	379
INFORMATION ABOUT VERSO INFORMATION ABOUT NEWPAGE Description of Business 390 391	COMPARISON OF RIGHTS OF HOLDERS OF VERSO COMMON STOCK AND NEWPAGE	
INFORMATION ABOUT NEWPAGE Description of Business 391	<u>COMMON STOCK</u>	380
Description of Business 391	INFORMATION ABOUT VERSO	390
Description of Business 391	INFORMATION ABOUT NEWPAGE	391
•		391
	Description of Property	400

Legal Proceedings	400
Management s Discussion and Analysis of Financial Condition and Results of Operations	400
Contractual Commitments	413
Quantitative and Qualitative Disclosures About Market Risk	413
LEGAL MATTERS	414
<u>EXPERTS</u>	414
WHERE YOU CAN FIND MORE INFORMATION	415
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS	F-1

iv

ANNEXES

<u>ANNEX A</u>	MERGER AGREEMENT	A-1
ANNEX B	OPINION OF FINANCIAL ADVISOR TO NEWPAGE	B-1
ANNEX C	SECTION 262 OF THE DELAWARE GENERAL CORPORATION LAW	C-1
ANNEX D	FAIRNESS OPINION OF FINANCIAL ADVISOR TO VERSO	D-1
ANNEX E	SOLVENCY OPINION OF FINANCIAL ADVISOR TO VERSO	E-1
ANNEX F	LOCK UP SIDE LETTER	F-1
ANNEX G	REGULATORY FILING LETTER	G-1
<u>ANNEX H</u>	DIRECTOR APPOINTMENT LETTER	H-1
<u>ANNEX I</u>	FORM OF COOPERATION AGREEMENT	I-1
ANNEX J	FORM OF RELEASE AGREEMENT	J-1
<u>ANNEX K</u>	AMENDED AND RESTATED 2008 INCENTIVE AWARD PLAN	K-1